RBC Capital analyzed Eli Lilly’s Phase 3 retatrutide results on March 20, following the company's March 19 announcement.
The firm reported that retatrutide demonstrated superior weight loss results compared to Mounjaro.
Analysis indicated that A1C reduction and overall tolerability were less favorable than Mounjaro.
RBC Capital identified the drug as a key pillar for future growth and margin expansion.
The bank maintained an Outperform rating on LLY stock with a $1,250 price target.
Analysts project a 2027 launch with sales reaching $4.9 billion by 2030.